Comprehensive lymphatic irradiation for stage II-III non-Hodgkin's lymphoma.
Thirteen patients with stage II-III non-Hodgkin's lymphoma (NHL) and one patient with minimal marrow involvement were selected for treatment between 1964 and 1986 with moderate-dose comprehensive lymphatic irradiation (CLI). This approach has been well tolerated and has produced relapse-free and overall survival rates at 10 years of 60 and 66%, respectively. Salvage therapy for failure following CLI has been possible. CLI produces results comparable to any achieved with combined modality therapy, offers less acute and late toxicity, and requires only 3-4 months for completion.
Mendenhall
N P
NP
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville.
Million
R R
RR
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015182:Lymphatic Irradiation; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D013997:Time Factors